tiprankstipranks
Xilio Therapeutics (XLO)
NASDAQ:XLO
US Market

Xilio Therapeutics (XLO) Income Statement

Compare
157 Followers

Xilio Therapeutics Income Statement

Last quarter (Q4 2024), Xilio Therapeutics's total revenue was $1.72M, a decrease of -40.59% from the same quarter last year. In Q4, Xilio Therapeutics's net income was $-13.09M. See Xilio Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 6.34M$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 6.34M$ -1.90M$ -1.85M$ -1.50M$ -1.06M
Operating Expenses
$ 66.93M$ 79.13M$ 89.15M$ 75.04M$ 54.56M
Depreciation and Amortization
$ 1.64M$ 1.90M$ 1.85M$ 1.50M$ 1.06M
EBITDA
$ -58.00M$ -73.80M$ -85.58M$ -73.70M$ -53.50M
Operating Income
$ -60.58M$ -79.13M$ -89.15M$ -75.04M$ -54.56M
Other Income/Expenses
$ 2.34M$ 2.73M$ 927.00K$ -756.00K$ -656.00K
Pretax Income
$ -58.24M$ -76.40M$ -88.22M$ -75.80M$ -55.22M
Net Income
$ -58.24M$ -76.40M$ -87.30M$ -74.30M$ -55.22M
Per Share Metrics
Basic EPS
$ -1.09$ -2.78$ -3.19$ -2.72$ -2.01
Diluted EPS
$ -1.09$ -2.78$ -3.19$ -2.72$ -2.01
Weighted Average Shares Outstanding
53.51M 27.50M 27.39M 27.36M 27.47M
Weighted Average Shares Outstanding (Diluted)
53.51M 27.50M 27.39M 27.36M 27.47M
Currency in USD

Xilio Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis